{
    "name": "CardioRelief",
    "indication": "Chronic Heart Failure (NYHA Class IIâ€“III)",
    "stage": "Phase IIb Clinical Trial",
    "target_market": "European Union, Malaysia, Singapore",
    "mechanism": "Selective Beta-3 Adrenergic Receptor Agonist",
    "dosage_form": "Oral tablet, 25 mg once daily",
    "sponsor": "PharmaNova Therapeutics",
    "principal_investigators": [
      {"name": "Dr. Aisha Rahman", "institution": "University of Malaya"},
      {"name": "Prof. John Tan", "institution": "National Heart Centre Singapore"}
    ],
    "trial_sites": [
      {"country": "Malaysia", "number_of_patients": 120},
      {"country": "Germany", "number_of_patients": 200},
      {"country": "Singapore", "number_of_patients": 80}
    ],
    "safety_profile": {
      "common_adverse_events": ["Mild dizziness", "Headache", "Nausea"],
      "serious_adverse_events": ["Rare cases of arrhythmia"],
      "discontinuation_rate": "5%"
    },
    "efficacy_signals": {
      "primary_endpoint": "Improvement in left ventricular ejection fraction (LVEF)",
      "secondary_endpoints": ["6-minute walk test", "Quality of Life (QoL) score"],
      "observed_effect": "10% relative improvement in LVEF after 12 weeks"
    },
    "competitors": [
      "Entresto (sacubitril/valsartan)",
      "Verquvo (vericiguat)"
    ],
    "regulatory_path": "EMA Conditional Approval followed by FDA Breakthrough Therapy Designation",
    "notes": "Strong efficacy signal but requires larger sample size for Phase III confirmation. Potential market differentiation through improved tolerability profile compared to existing therapies."
  }
  